Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Pharmaceuticals sales up 3%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

1Q Revenues: $11.7 billion (+1%)

1Q Earnings: $1.7 billion (+67%)

Comments: Pharmaceuticals sales were up 3%, driven by Januvia, up 24% to $919 million, Victrelis sales of $111 million, Janumet, up 29% to $392 million, Gardasil, up 33% to $284 million, Zostavax, up 68% to $76 million, and Isentress, up 15% to $337 million. Remicade sales declined 31% to $519 million as a result of territories transferred to Johnson & Johnson as a result of the arbitration settlement agreement Cozaar/Hyzaar sales dropped 21% to $336 million due to generic competition. Animal Health sales were up 8% and Consumer Care was up 7%. Alliance revenue, miscellaneous corporate revenues and third-party manufacturing sales declined 43% to $274 million, driven by lower revenue from AstraZeneca LP recorded by Merck, which declined 42% to $186 million, as well as by lower third-party manufacturing sales partially due to the divestiture of certain manufacturing facilities in 2011. Acquisition-related costs were $1.3 billion compared to $1.7 billion in 1Q11.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters